glp 1 gip dual agonist Main physiological actions of the and GLP-1 Targeting GLP-1, GIP & GCG

But what if GLP-1 drugs could offer another way out

A global retrospective cohort study utilizing data from the TriNetX global network similarly reported a significant association between GLP-1RAs treatment and a lower AF and arrhythmias risk in individuals with obesity and without T2DM [30]

In the trials, individuals with diabetes lost less weight with these medications than those without diabetes

Once-Weekly Semaglutide in Adults With Overweight or Obesity

This increase of FFA in the liver and circulation results in hypertriglyceridemia, pronounced in the postprandial period, and fasting dyslipidemia leading to insulin resistance, obesity, and unfavorable changes to the cardiometabolic profile [10, 11]

In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding